Immunic, Inc. to Announce Financial Results for the First Quarter Ended March 31, 2022 and Provide Corporate UpdatePRNewsWire • 05/03/22
Immunic, Inc. Announces Promotion of Glenn Whaley, CPA to Chief Financial OfficerPRNewsWire • 03/16/22
Immunic Inc. (IMUX) CEO Daniel Vitt on Q4 2021 Results - Earnings Call TranscriptSeeking Alpha • 02/24/22
Immunic, Inc. Reports Year End 2021 Financial Results and Highlights Recent ActivityPRNewsWire • 02/24/22
Immunic, Inc. to Present Preclinical Data for Vidofludimus Calcium at the 17th Congress of European Crohn's and Colitis Organization and Announces Blinded Baseline Characteristics of its Phase 2 CALDOSE-1 Trial of Vidofludimus Calcium in Ulcerative ColitiPRNewsWire • 02/18/22
Immunic, Inc. to Announce Financial Results for the Year Ended December 31, 2021 and Provide Corporate UpdatePRNewsWire • 02/17/22
Immunic Receives Notice of Allowance for Composition-of-Matter Patents in the United States and in Europe for IMU-935, a Potentially Best-in-Class Oral IL-17 InhibitorPRNewsWire • 02/02/22
Can Immunic (IMUX) Climb 357% to Reach the Level Wall Street Analysts Expect?Zacks Investment Research • 01/11/22
Immunic, Inc. Publishes Positive Results from the Single and Multiple Ascending Dose Parts of its Phase 1 Clinical Trial of IMU-935, a Potentially Best-in-Class Oral IL-17 InhibitorPRNewsWire • 12/14/21
Immunic, Inc. Announces Enrollment of the First Patient in its Phase 1 Trial of IMU-935 in Metastatic Castration-Resistant Prostate CancerPRNewsWire • 12/09/21
Immunic, Inc. to Participate in the Piper Sandler & Co. 33rd Annual Virtual Healthcare ConferencePRNewsWire • 11/23/21
Immunic, Inc. Announces Enrollment of First Patient in its Phase 3 ENSURE Program of vidofludimus calcium (IMU-838) in Relapsing Multiple SclerosisPRNewsWire • 11/18/21
Immunic, Inc. (IMUX) CEO Daniel Vitt on Q3 2021 Results - Earnings Call TranscriptSeeking Alpha • 11/06/21
Immunic, Inc. Reports Third Quarter 2021 Financial Results and Highlights Recent ActivityPRNewsWire • 11/04/21
Immunic, Inc. to Announce Financial Results for the Third Quarter Ended September 30, 2021 and Provide Corporate UpdatePRNewsWire • 11/01/21
Immunic, Inc. Announces Completion of Enrollment of its Phase 2 CALDOSE-1 Trial of IMU-838 in Moderate-to-Severe Ulcerative ColitisPRNewsWire • 10/28/21
Immunic, Inc. Announces First Psoriasis Patient Enrolled in Ongoing Phase 1 Trial of IMU-935PRNewsWire • 10/27/21
Immunic, Inc. Enrolls First Patient in Its Phase 2 CALLIPER Trial of IMU-838 in Progressive Multiple SclerosisPRNewsWire • 09/30/21
Immunic, University Medical Center Goettingen Ink Licensing Pact For Combination Viral Infection TreatmentsBenzinga • 09/22/21